Literature DB >> 7200773

Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production.

E J Hornby, I F Skidmore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7200773     DOI： 10.1016/0006-2952(82)90359-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  8 in total

Review 1.  Thromboxane synthase inhibitors and receptor antagonists.

Authors:  J Vermylen; H Deckmyn
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

2.  The antiplatelet activity of PMC, a potent alpha-tocopherol analogue, is mediated through inhibition of cyclo-oxygenase.

Authors:  J R Sheu; C R Lee; C C Lin; Y C Kan; C H Lin; W C Hung; Y M Lee; M H Yen
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 3.  Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.

Authors:  H Patscheke
Journal:  Blut       Date:  1990-05

4.  Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.

Authors:  J P De La Cruz; M A Villalobos; R Escalante; A Guerrero; M M Arrebola; F Sánchez de La Cuesta
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

5.  Low concentration of oxidized low density lipoprotein suppresses platelet reactivity in vitro: an intracellular study.

Authors:  Duen-Suey Chou; George Hsiao; Ming-Yi Shen; Tsorng-Harn Fong; Chien-Huang Lin; Tzeng-Fu Chen; Joen-Rong Sheu
Journal:  Lipids       Date:  2004-05       Impact factor: 1.880

6.  Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies.

Authors:  Joen R Sheu; Tsorng H Fong; Cheng M Liu; Ming Y Shen; Ta L Chen; Yi Chang; Meng S Lu; George Hsiao
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

7.  Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.

Authors:  I S Watts; K A Wharton; B P White; P Lumley
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

8.  Inhibitory effect of a selective thromboxane A2 receptor antagonist, EP 092, on platelet aggregation in whole blood ex vivo and in vivo.

Authors:  R F Booth; A C Honey; N Lad; D P Tuffin; P J Wade
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.